Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

725
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
725
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

591
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
591
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

636
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
636
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

732
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
732
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

511
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
511
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 'CIED Team' Approach to Device-Related Complications.

JACC. Case reports·2026
Same author

Deep ensemble optimized models for probabilistic CTV breast segmentation.

Frontiers in artificial intelligence·2026
Same author

Subcutaneous ICD therapy in patients with prior sternotomy: feasibility and long-term outcomes in a propensity-matched analysis from a national registry.

Heart rhythm·2026
Same author

Estimated longevity of contemporary subcutaneous implantable cardioverter-defibrillators: Multicenter real-world data.

Heart rhythm O2·2026
Same author

Coronary CT angiography in master athletes: Redefining primary prevention of ischemic heart disease beyond the Italian 2023 COCIS guidelines.

International journal of cardiology·2026
Same author

Exercise practice and short-QT interval on ECG.

Journal of electrocardiology·2025

Related Experiment Video

Updated: Mar 19, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Cardiac resynchronization therapy improves functional status and cognition.

Stefano Fumagalli1, Paolo Pieragnoli2, Giuseppe Ricciardi2

  • 1Intensive Care Unit, Division of Geriatric Cardiology and Medicine, and Research Unit of Medicine of Aging, Department of Experimental and Clinical Medicine, University of Florence and AOU Careggi, Florence, Italy.

International Journal of Cardiology
|June 23, 2016
PubMed
Summary
This summary is machine-generated.

Cardiac resynchronization therapy (CRT) significantly improved functional performance and cognition in heart failure patients within six months. This therapy may help slow the development of disability and frailty.

Keywords:
Cardiac resynchronization therapyCognitive impairmentElderlyFrailtyHeart failureSPPB

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.1K
Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

2.0K

Related Experiment Videos

Last Updated: Mar 19, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.1K
Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

2.0K

Area of Science:

  • Cardiology
  • Geriatrics
  • Neurology

Background:

  • Cardiac resynchronization therapy (CRT) is known to reduce hospitalizations and mortality.
  • Functional performance and cognition are key determinants of disability, frailty, and survival in heart failure patients.

Purpose of the Study:

  • To evaluate the effects of CRT on functional performance and cognition in heart failure patients.

Main Methods:

  • 54 consecutive patients receiving CRT were assessed at baseline and 6-month follow-up.
  • Functional status was measured using the Short Physical Performance Battery (SPPB).
  • Cognitive function was assessed using the Mini-Mental State Examination (MMSE).

Main Results:

  • After 6 months, CRT improved left ventricular ejection fraction (LVEF), NYHA class, and reduced left ventricular end-systolic diameter.
  • Significant improvements were observed in SPPB scores, including gait speed, strength, and endurance.
  • CRT was associated with enhanced cognitive function, as indicated by MMSE scores.

Conclusions:

  • Cardiac resynchronization therapy positively impacts both functional and cognitive profiles in heart failure patients within 6 months.
  • These findings suggest CRT may play a role in mitigating disability and frailty progression in heart failure.